In Vitro and In Vivo Activity of Hamycin Against Blastomyces dermatitidis1
AUTOR(ES)
Shadomy, Smith
RESUMO
Clinical responses of patients with blastomycosis to treatment with hamycin have been variable. An explanation for this was sought in a series of studies in which in vitro and in vivo susceptibilities to hamycin of five strains of Blastomyces dermatitidis were compared. Minimal inhibitory concentrations of hamycin for the five strains indicated uniformly high levels of in vitro susceptibility (0.008 to 0.016 μg/ml). In vivo activity was measured in infected mice treated intraperitoneally for a period of 28 days with doses of the drug ranging from 0.001 to 0.030 mg per mouse. Significant differences in response to treatment among the five strains were noted (P < 0.001), and protective doses were found to vary from 0.001 to >0.030 mg per mouse per day. Further observations of infected mice after treatment revealed marked rates of relapsing infection, and several strains caused death. Persistent inapparent infections were also detected on culture of selected organs. Toxicity due to hamycin alone was not observed. These results suggest that variations in clinical responses to hamycin therapy in treatment of blastomycosis reflect differences in pathogenesis and host response in vivo to the infecting organism rather than differences in susceptibility of B. dermatitidis to hamycin.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=249715Documentos Relacionados
- In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis.
- BIOTIN AS A GROWTH REQUIREMENT FOR BLASTOMYCES DERMATITIDIS1
- TISSUE CULTURES OF MOUSE PERITONEAL EXUDATES INOCULATED WITH BLASTOMYCES DERMATITIDIS1
- Deoxyribonucleic Acid Base Composition of the Yeastlike and Mycelial Phases of Histoplasma capsulatum and Blastomyces dermatitidis1
- In Vivo and In Vitro Cell-Mediated Immune Responses to a Cell Wall Antigen of Blastomyces dermatitidis